文献速递心力衰竭与心肌病

SGLT2抑制剂在射血分数保留的心力衰竭中获益的机制

Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
PubMed 文献 · Eur Heart J · 2023-01-01

该综述基于DELIVER和EMPEROR-Preserved等试验,总结SGLT2抑制剂在HFpEF中降低心衰住院或心血管死亡复合终点的机制。除降糖、降压和延缓肾病进展外,临床前与转化研究提示其可诱导营养剥夺和缺氧样转录模式、增加酮症、促红细胞生成素和自噬流、改变铁稳态、减少心外膜脂肪组织、影响心肌细胞离子稳态、降低心肌丝僵硬度及细胞外基质重构/纤维化,从而改善心脏能量学和舒张功能。

要点

  • DELIVER和EMPEROR-Preserved显示SGLT2抑制剂降低HFpEF心衰住院或心血管死亡复合终点。
  • 机制涉及营养剥夺/缺氧样转录、酮症、促红细胞生成素、自噬流和铁稳态改变。
  • SGLT2抑制剂减少心外膜脂肪组织、炎症和氧化应激,并改善舒张功能。

核心结论

  • SGLT2抑制剂已成为稳健的疾病修饰疗法,并可能成为HFpEF治疗的基础。

研究设计与样本

  • 综述总结DELIVER和EMPEROR-Preserved等里程碑试验及临床前与转化研究证据。

主要发现

  • SGLT2抑制剂诱导营养剥夺和缺氧样转录模式,增加酮症、促红细胞生成素和自噬流,并改变铁稳态。
  • SGLT2抑制剂减少心外膜脂肪组织并改变脂肪因子信号,可能减少炎症和氧化应激。
  • SGLT2抑制剂影响心肌细胞离子稳态,但机制尚未明确。
  • SGLT2抑制剂降低心肌丝僵硬度及细胞外基质重构/纤维化,改善舒张功能。

临床怎么用

  • SGLT2抑制剂可作为HFpEF的疾病修饰治疗选择,并可能成为基础治疗。

局限性

  • 心肌细胞离子稳态影响是否通过间接机制或其他离子通道的脱靶效应尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to reduce the composite of heart failure hospitalization or cardiovascular death in patients with HFpEF in the landmark DELIVER and EMPEROR-Preserved trials. While improvements in blood sugar, blood pressure, and attenuation of kidney disease progression all may play some role, preclinical and translational research have identified additional mechanisms of these agents. The SGLT2 inhibitors have intriguingly been shown to induce a nutrient-deprivation and hypoxic-like transcriptional paradigm, with increased ketosis, erythropoietin, and autophagic flux in addition to altering iron homeostasis, which may contribute to improved cardiac energetics and function. These agents also reduce epicardial adipose tissue and alter adipokine signalling, which may play a role in the reductions in inflammation and oxidative stress observed with SGLT2 inhibition. Emerging evidence also indicates that these drugs impact cardiomyocyte ionic homeostasis although whether this is through indirect mechanisms or via direct, off-target effects on other ion channels has yet to be clearly characterized. Finally, SGLT2 inhibitors have been shown to reduce myofilament stiffness as well as extracellular matrix remodelling/fibrosis in the heart, improving diastolic function. The SGLT2 inhibitors have established themselves as robust, disease-modifying therapies and as recent trial results are incorporated into clinical guidelines, will likely become foundational in the therapy of HFpEF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Pandey, Bhatt, Pandey, et al. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023. PMID: 37674356. doi:10.1093/eurheartj/ehad389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。